Connect with us

Hi, what are you looking for?

Tuesday, May 30, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Lobe Sciences acquires rare blood disease treatment company

Lobe’s primary focus is psychedelic medicines but the company also has an interest in treating rare disorders

Vancouver's Lobe Sciences acquires Sickle Cell Disease treatment company
Sickle Cell Disease causes red blood cells to have a crescent shape. Photo via Altemia & Company

Vancouver-based Lobe Sciences Ltd (CSE: LOBE) (OTCQB: LOBEF), a psychedelic medicine developer, has inked an agreement to acquire a Florida company specializing in the treatment of Sickle Cell Disease (SCD), a rare blood disorder caused by defective hemoglobin.

Lobe announced the acquisition of Altemia & Company, LLC on Tuesday and will be receiving all of its intellectual property, assets and product inventory in a deal valued at $3.8 million.

Lobe says the move has affirmed its position as a rare disease drug development company in addition to its involvement with psychedelics and expects to generate revenue from Altemia’s flagship SCD treatment product (also called Altemia) by the second half of this year.

Read more: LSD helps alleviate anxiety and major depression symptoms: MindMed

Read more: Numinus Wellness YoY revenue increased five times to $5.4M

Lobe has acquired two SCD management drugs

In addition to Altemia, Lobe will also be acquiring SAN100 from the company — a proprietary drug being developed for the treatment of SCD in children specifically.

“Starting in the second half of 2023 we will launch our first commercial product, a medical food called Altemia for the management of SCD,” said Lobe’s CEO Philip J. Young.

Altemia is a cream-like substance in a packet that can be taken orally by itself or mixed with food daily. It tastes great, according to Altemia’s Founder and President Frederick Sancilio.

“This product has been well studied in human clinical trials. It is a proprietary, patent-pending formulation based on decades of research and will add commercial revenue this year and beyond,” added Young.

SCD impacts about 100,000 United States citizens and millions of people around the globe. The disease is inherited through one’s genetics, according to the Centers for Disease Control and Prevention (CDC).

“We believe that Altemia and our follow-on prescription product, SAN100, will become an important component in the daily lives of patients with SCD around the world,” said Maghsoud Dariani, Chief Science Officer of Altemia & Company, LLC.

Read more: Dutch government establishes MDMA research commission

Read more: Lobe Sciences partners with iNGENū for new clinical trials in Australia

Lobe recently offered its congratulations to Australia for becoming the first country to approve the medicinal use of MDMA and psilocybin. In August last year, Lobe partnered with the contract research organization iNGENū Pty Ltd. to help orchestrate a series of clinical trials with its proprietary psilocin analogues L-130 and L-131 in the country.

Lobe’s shares are currently worth $0.03 on the Canadian Securities Exchange and OTC Markets.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter












Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Natural Medicine Health act will take effect on July 1


The group aims to foster EU-funded research on psychedelics and promote drug policies based on scientific evidence


The study has been approved by the Clinical Trials Registry


The survey running until June 2 is sponsored by MAPS, Mind Medicine Australia, SABI Mind and Tiny